Patents Examined by Hazel F. Sidberry
-
Patent number: 5780040Abstract: The application discloses a nickel binding protein and its encoding DNA isolated from Helicobacter pylori. This organism is the primary cause of chronic gastritis and ensuing peptic ulcers, and has been implicated in stomach cancer. The nickel binding protein is useful to inhibit assembly of active ureases, the enzymes responsible for the pathogenic features of the bacterium. Potential uses include as a vaccine, a diagnostic, a drug target, and a therapy in itself.Type: GrantFiled: June 8, 1994Date of Patent: July 14, 1998Assignees: Tufts University School of Medicine Hospital, Inc., New England Medical Center Hospital, Inc.Inventors: Andrew G. Plaut, Joanne V. Gilbert-Rothstein, Andrew Wright
-
Patent number: 5770694Abstract: The present invention provides a composition comprising a BPI Protein and an anionic compound which composition exhibits (1) no bactericidal activity and (2) endotoxin neutralizing activity. Also, this invention provides methods for using BPI Proteins.Type: GrantFiled: July 22, 1992Date of Patent: June 23, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Randal W. Scott, Marian N. Marra
-
Patent number: 5770213Abstract: The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of non-typable Haemophilus influenzae infection.Type: GrantFiled: May 5, 1994Date of Patent: June 23, 1998Assignee: American Cyanamid CompanyInventor: Gary W. Zlotnick
-
Patent number: 5766608Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.Type: GrantFiled: June 1, 1995Date of Patent: June 16, 1998Assignee: The Ohio State Research FoundationInventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova
-
Patent number: 5753787Abstract: A protein, Ancylostoma Secreted Protein (ASP), that is released by hookworm larvae following infection, and which is highly immunogenic in experimental animals, is disclosed. Nucleic acids encoding ASP, antibodies recognizing ASP, and methods of detecting ASP, nucleic acids encoding ASP, and antibodies recognizing ASP, in a sample are also disclosed. ASP is useful in a vaccine for hookworm as well as other soil-transmitted human and veterinary nematodiases. ASP is also useful as a target for specific treatment of hookworm, and can be used in a diagnostic assay for hookworm, using standard protein detection techniques, especially those based on antibodies. DNA encoding ASP is useful both for producing ASP recombinantly and in a diagnostic assay for hookworm. Antibodies recognizing ASP are useful in diagnostic assays to detect protein produced during hookworm infection.Type: GrantFiled: April 10, 1995Date of Patent: May 19, 1998Assignee: Yale UniversityInventors: John M. Hawdon, Peter J. Hotez, Brian F. Jones
-
Patent number: 5753238Abstract: The present invention relates novel methods and compositions for blocking transmission of Plasmodium spp. which cause malaria. In particular, P28 proteins are disclosed which, when administered to a susceptible organism, induce an immune response against a 28 kD protein on the surface of Plasmodium ookinetes and block transmission of malaria.Type: GrantFiled: May 30, 1995Date of Patent: May 19, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David C. Kaslow, Patrick E. Duffy
-
Patent number: 5730980Abstract: The present invention concerns a method of treating CD14-mediated host inflammatory response to LPS often associated with sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: GrantFiled: October 25, 1994Date of Patent: March 24, 1998Assignee: The Scripps Research InstituteInventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
-
Patent number: 5721348Abstract: The disclosure relates to isolated DNA encoding all or a portion of a surface protein present in sperm of a mammal. This surface protein of sperm is essential for fertilization in the mammal. Preferably, the sperm surface protein is the PH-20 protein.Type: GrantFiled: October 21, 1991Date of Patent: February 24, 1998Assignee: University of ConnecticutInventors: Paul Primakoff, Diana G. Myles
-
Patent number: 5721349Abstract: An isolated nucleic acid encoding the Helicobacter pylori vacuolating toxin, consisting of the nucleotides 101 through 3964 of the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. An isolated nucleic acid from Helicobacter pylori comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:3 is provided. Isolated nucleic acids that selectively hybridize with the nucleic acids of the invention are provided. Also provided is a genetically altered mutant strain of H. pylori that does not express a functional vacuolating toxin. Purified proteins encoded by the nucleic acids of the invention are provided. A composition comprising an immunogenic amount of a protein or mutant strain of the invention in a pharmaceutically acceptable carrier is provided. A method of immunizing a subject against infection by H. pylori, comprising administering to the subject an immunogenic composition of the invention is provided.Type: GrantFiled: February 23, 1994Date of Patent: February 24, 1998Assignee: Vanderbilt UniversityInventors: Timothy L. Cover, Martin J. Blaser
-
Patent number: 5702708Abstract: A treatment of fish for infection by the organism Aeromonas salmonicida using either one or both of two components produced by a culture of the organism. The culture is treated to kill the organisms prior to use, preferably by treatment with formalin after the components have been produced. One of the components, only produced when the culture is grown under iron limiting conditions induces production of antibodies which cause death of the organisms when injected intraperitoneally into fish.Type: GrantFiled: January 4, 1994Date of Patent: December 30, 1997Assignee: The Secretary of State for Scotland in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern IrelandInventor: Anthony E. Ellis
-
Patent number: 5695769Abstract: This invention provides vaccine compositions, methods of producing same and methods for protecting porcine animals against disease associated with infection by toxigenic Pasteurella multocida. The vaccines of this invention contain effective amounts of a P. multocida bacterin with a cell-bound toxoid and, optionally, a P. multocida free toxoid.Type: GrantFiled: July 11, 1994Date of Patent: December 9, 1997Assignee: Pfizer Inc.Inventors: Joseph C. Frantz, David S. Roberts, Leroy A. Swearingin, Richard J. Kemmy
-
Patent number: 5688512Abstract: Disclosed and claimed are substantially pure OspA, vaccines including substantially pure OspA and an immunologically acceptable carrier or vehicle, methods for producing such vaccines, and methods for inducing a protective immunological response against Borrelia burgdorferi employing such vaccines. The methods for producing the vaccines can include admixing the OspA and the carrier or vehicle. The methods for producing the vaccines also can include recovering the OspA from a host organism transformed with a vector containing DNA encoding the OspA and admixing the OspA with an immunologically acceptable carrier or vehicle. Such methods can further include adding an adjuvant. The vaccine can contain OspA from two or more strains of Borrelia burgdorferi.Type: GrantFiled: January 20, 1995Date of Patent: November 18, 1997Assignee: Symbicom AktiebolagInventors: Sven Bergstrom, Alan G. Barbour
-
Patent number: 5688513Abstract: The invention provides an immunogenic polypeptide having the amino acid sequence ##STR1## and fragments thereof, which polypeptides are capable of inducing an immune response against Eimeria parasites, and the DNA encoding such polypeptides, as well as recombinant vectors and recombinant viruses containing the said DNA or fragments thereof and transformed microorganisms containing such vectors and viruses and coccidiosis vaccines comprising such polypeptides.Type: GrantFiled: June 9, 1994Date of Patent: November 18, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Mary-Helen Binger, Luis Pasamontes
-
Patent number: 5686080Abstract: The present invention relates to isolated parasitic helminth nucleic acid sequences capable of hybridizing, under stringent conditions, to at least a portion of D. immitis nucleic acid sequence p4 and/or to at least a portion of D. immitis nucleic acid sequence p22U; to isolated parasitic helminth proteins that are encoded by such parasitic helminth nucleic acid sequences and that are capable of selectively binding to at least one component of immune serum capable of inhibiting helminth development; and to antibodies raised against such isolated parasitic helminth proteins. The present invention also relates to therapeutic compositions comprising such isolated nucleic acid sequences, proteins and/or antibodies. The present invention also includes methods to produce and use such nucleic acids, proteins, antibodies and therapeutic compositions capable of protecting animals from parasitic helminth infection and, particularly, from heartworm infection.Type: GrantFiled: June 2, 1995Date of Patent: November 11, 1997Assignees: Heska Corporation, Colorado State University Research FoundationInventors: Cynthia Ann Tripp, Glenn Robert Frank, Robert B. Grieve
-
Patent number: 5684145Abstract: The present invention is concerned with vaccination of mammals against GnRH. The vaccine comprises a GnRH peptide conjugate to E. coli fimbrial-filaments and elicits an immune response against GnRH.Type: GrantFiled: May 30, 1995Date of Patent: November 4, 1997Assignee: AKZO Nobel N.V.Inventors: Anna Van Der Zee, Irma Marianne Van Die, Willem Pieter Martin Hoekstra, Josephus Theodorus Gielen
-
Patent number: 5677438Abstract: The invention is concerned with a protein having the immunological properties of Eimeria tenella which is reactive with a monoclonal antibody E. TEN 11P-2 raised against E. tenella sporozoites.The invention also relates to polypeptide fragments of this protein which can be used for immunization against E. tenella. These proteins and polypeptides can be prepared by isolation from E. tenella, by chemical synthesis or by recombinant DNA methods using the polynucleotides described herein or related sequences.Type: GrantFiled: March 27, 1990Date of Patent: October 14, 1997Assignee: Akzo Nobel N.V.Inventors: Lorraine Elizabeth Clarke, Fiona Margaret Tomley, Rein Dijkema, Arno Vermeulen
-
Patent number: 5674503Abstract: The present invention provides immunogens suitable for vaccination against leishmaniasis.Type: GrantFiled: September 21, 1994Date of Patent: October 7, 1997Assignee: University of VictoriaInventor: Robert W. Olafson
-
Patent number: 5653986Abstract: Substantially pure capsular polysaccharide obtained from Vibrio cholerae Bengal serogroup-O139, capsular polysaccharide-protein conjugates thereof, and antibodies having binding specificity to said capsular polysaccharide.Type: GrantFiled: June 6, 1995Date of Patent: August 5, 1997Assignee: University of Maryland at BaltimoreInventors: J. Glenn Morris, Jr., Judith A. Johnson, C. Allen Bush
-
Patent number: 5648080Abstract: The invention provides a vaccine containing a proteinaceous material derived from the outer membrane of Bordetella pertussis, wherein the proteinaceous material is characterized by a relative molecular weight of 67,000 to about 73,000, preferably 69,000, as determined by 12% (w/w) polyacrylamide gel electrophoresis, and has a proline:glutamic acid ratio of about 1:1, in a pharmaceutically acceptable carrier or adjuvant. The invention also provides a method of inducing an immune response in an individual involving administering the vaccine of the invention to an individual.Type: GrantFiled: March 21, 1994Date of Patent: July 15, 1997Assignee: Evans Medical LimitedInventor: Pavel Novotny
-
Patent number: 5648081Abstract: The present invention is concerned with vaccines effective in protecting pigs against porcine pleuropneumonia. Said vaccines comprising a hemolysin and/or macrophage toxin and a 42 kD OMP preparation derived from Actinobacillus pleuropneumoniae (App) cells induce a complete and heterologous protection against App infection.Type: GrantFiled: January 3, 1995Date of Patent: July 15, 1997Assignee: Akzo Nobel N.V.Inventor: Johannes Franciscus van den Bosch